89Zr-贝伐珠单抗 PET 显像用于原发性乳腺癌。

89Zr-bevacizumab PET imaging in primary breast cancer.

机构信息

Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.

出版信息

J Nucl Med. 2013 Jul;54(7):1014-8. doi: 10.2967/jnumed.112.117218. Epub 2013 May 7.

DOI:10.2967/jnumed.112.117218

PMID:23651946

Abstract

UNLABELLED

Vascular endothelial growth factor (VEGF)-A is overexpressed in most malignant and premalignant breast lesions. VEGF-A can be visualized noninvasively with PET imaging and using the tracer (89)Zr-labeled bevacizumab. In this clinical feasibility study, we assessed whether VEGF-A in primary breast cancer can be visualized by (89)Zr-bevacizumab PET.

METHODS

Before surgery, breast cancer patients underwent a PET/CT scan of the breasts and axillary regions 4 d after intravenous administration of 37 MBq of (89)Zr-bevacizumab per 5 mg. PET images were compared with standard imaging modalities. (89)Zr-bevacizumab uptake was quantified as the maximum standardized uptake value (SUV max). VEGF-A levels in tumor and normal breast tissues were assessed with enzyme-linked immunosorbent assay. Data are presented as mean ± SD.

RESULTS

Twenty-five of 26 breast tumors (mean size ± SD, 25.1 ± 19.8 mm; range, 4-80 mm) in 23 patients were visualized. SUV max was higher in tumors (1.85 ± 1.22; range, 0.52-5.64) than in normal breasts (0.59 ± 0.37; range, 0.27-1.69; P < 0.001). The only tumor not detected on PET was 10 mm in diameter. Lymph node metastases were present in 10 axillary regions; 4 could be detected with PET (SUV max, 2.66 ± 2.03; range, 1.32-5.68). VEGF-A levels in the 17 assessable tumors were higher than in normal breast tissue in all cases (VEGF-A/mg protein, 184 ± 169 pg vs. 10 ± 21 pg; P = 0.001), whereas (89)Zr-bevacizumab tumor uptake correlated with VEGF-A tumor levels (r = 0.49).

CONCLUSION

VEGF-A in primary breast cancer can be visualized by means of (89)Zr-bevacizumab PET.

摘要

未加说明

血管内皮生长因子（VEGF）-A 在大多数恶性和癌前病变的乳腺病变中过度表达。VEGF-A 可以通过 PET 成像和使用示踪剂（89）Zr 标记的贝伐单抗进行无创可视化。在这项临床可行性研究中，我们评估了原发性乳腺癌中的 VEGF-A 是否可以通过（89）Zr-贝伐单抗 PET 进行可视化。

方法

在手术前，乳腺癌患者在静脉注射 37MBq（89）Zr-贝伐单抗（每 5mg）后 4 天接受乳房和腋窝区域的 PET/CT 扫描。将 PET 图像与标准成像方式进行比较。（89）Zr-贝伐单抗摄取量被量化为最大标准化摄取值（SUVmax）。使用酶联免疫吸附测定法评估肿瘤和正常乳腺组织中的 VEGF-A 水平。数据表示为平均值±标准差。

结果

23 名患者的 26 个乳房肿瘤中有 25 个（平均大小±标准差，25.1±19.8mm；范围，4-80mm）可被可视化。肿瘤的 SUVmax 高于正常乳房（1.85±1.22；范围，0.52-5.64）（0.59±0.37；范围，0.27-1.69；P<0.001）。唯一未在 PET 上检测到的肿瘤直径为 10mm。10 个腋窝区域存在淋巴结转移；4 个可通过 PET 检测到（SUVmax，2.66±2.03；范围，1.32-5.68）。在所有情况下，17 个可评估肿瘤的 VEGF-A 水平均高于正常乳腺组织（VEGF-A/mg 蛋白，184±169pg 比 10±21pg；P=0.001），而（89）Zr-贝伐单抗肿瘤摄取与 VEGF-A 肿瘤水平相关（r=0.49）。